Thomas E. Witzig

Also affiliated with WinnMed, Mayo Clinic in Arizona

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.1Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Papers

Driven by 43 papers — median percentile 90. Top paper: “The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes”.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis

Blood(1999)10.1182/blood.v93.3.1062.403k34_1062_1066

N/A

1.5DataRank · unranked

27 citations

Morie A. Gertz, Philip R. Greipp, Thomas E. Witzig, John A. Lust, Martha Q. Lacy +2 more

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine(2017)10.1056/nejmoa1707447

N/A

1.3DataRank · unranked

5812 citations

Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson +41 more

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1345

N/A

0.851DataRank · unranked

22 citations

Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig +11 more

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Blood(2024)10.1182/blood.2024024962

N/A

0.472DataRank · unranked

13 citations

Jenna Fernandez, Terra L. Lasho, Christy M. Finke, Michelle Amundson, Kristen McCullough +8 more

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

Nature Communications(2021)10.1038/s41467-021-23186-w

N/A

0DataRank · unranked

100 citations

Denis Vorobyev, Terra L. Lasho, David L. Marks, Ezequiel J. Tolosa, Alexis Vedder +30 more

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma

Blood Cancer Journal(2021)10.1038/s41408-021-00521-4

N/A

0DataRank · unranked

66 citations

Angelo Famà, Melissa C. Larson, Andrew L. Feldman, José C. Villasboas, Zhi-Zhang Yang +20 more

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

American Journal of Hematology(2021)10.1002/ajh.26230

N/A

0DataRank · unranked

24 citations

Melissa C. Larson, Alessia Castellino, Joerg Herrmann, David J. Inwards, Gita Thanarajasingam +10 more

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

Blood Cancer Journal(2021)10.1038/s41408-020-00394-z

N/A

0DataRank · unranked

17 citations

Aung M. Tun, Yucai Wang, Thomas M. Habermann, Rebecca L. King, Kay M. Ristow +7 more

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis

Blood Cancer Journal(2021)10.1038/s41408-021-00447-x

N/A

0DataRank · unranked

6 citations

Linda Wellik, Matthew J. Maurer, Ellen D. McPhail, Thomas E. Witzig, Mamta Gupta +1 more

Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia

Scientific Reports(2021)10.1038/s41598-021-87890-9

N/A

0DataRank · unranked

3 citations

Henan Zhang, Pan Zhang, Michael T. Kalmbach, Jeong‐Heon Lee, Tamás Ördög +9 more

Secreted ORF8 is a pathogenic cause of severe COVID-19 and is potentially targetable with select NLRP3 inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.12.02.470978

N/A

0DataRank · unranked

14 citations

Michelle K. Manske, Gordon Ruan, Taylor L. Witter, Kevin E. Nowakowski, Jithma P. Abeykoon +14 more

A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate

Kidney International Reports(2022)10.1016/j.ekir.2022.03.013

N/A

0DataRank · unranked

9 citations

Kianoush Kashani, Kristin C. Mara, Andrew D. Rule, John C. Lieske, Callen D. Giesen +5 more

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Hematological Oncology(2022)10.1002/hon.3098

N/A

0DataRank · unranked

7 citations

Raphael Mwangi, Alexandra N. Smith, Matthew J. Maurer, Umar Farooq, Rebecca L. King +9 more

Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma

Clinical Lymphoma Myeloma & Leukemia(2022)10.1016/j.clml.2022.03.004

N/A

0DataRank · unranked

8 citations

Jennifer Peterson, Bradford S. Hoppe, Jennifer Jiang, Gregory A. Wiseman, Thomas E. Witzig +2 more

The Tumor Suppressor Protein TRAF3 Modulates GSK3 Activity and Susceptibility of B Lymphoma Cells to GSK3 Inhibition

Cancers(2022)10.3390/cancers14205029

N/A

0DataRank · unranked

5 citations

Laura L. Stunz, Shakoora Sabree, Xiaosheng Wu, Thomas E. Witzig, Gail A. Bishop +1 more

Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with TET2-mutant clonal cytopenias of undetermined significance.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7076

N/A

0DataRank · unranked

3 citations

Terra L. Lasho, Jenna Fernandez, Christy M. Finke, Michelle Amundson, Betsy LaPlant +4 more

Methylated DNA markers in early detection of lymphoma: Discovery, validation, and clinical pilot.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7562

N/A

0DataRank · unranked

0 citations

William R. Taylor, Douglas W. Mahoney, William R. Bamlet, Patrick H. Foote, Kelli N. Burger +15 more

Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19

iScience(2023)10.1016/j.isci.2023.106929

N/A

0DataRank · unranked

18 citations

Michelle K. Manske, Gordon Ruan, Taylor L. Witter, Kevin E. Nowakowski, Jithma P. Abeykoon +14 more

Development and validation of a model to predict acute kidney injury following high‐dose methotrexate in patients with lymphoma

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy(2023)10.1002/phar.2889

N/A

0DataRank · unranked

7 citations

Erin F. Barreto, Andrew D. Rule, Catherine E. Martin, Huong L. Truong, Kristin C. Mara +5 more

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Blood Cancer Journal(2023)10.1038/s41408-023-00942-3

N/A

0DataRank · unranked

9 citations

Jennifer Gile, Melissa C. Larson, Kittika Poonsombudlert, Reema Tawfiq, Seth Maliske +14 more

Dependence of peripheral T‐cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach

Hematological Oncology(2023)10.1002/hon.3233

N/A

0DataRank · unranked

2 citations

J Vollenweider, Jingjing Han, Nicholas Staudinger, Mary Stenson, Lara Bayraktar +6 more

Tissue Inhibitor Metalloproteinase-2 and Insulin-Like Growth Factor Binding Protein-7 Kinetics Following Exposure to High-Dose Methotrexate

Kidney360(2023)10.34067/kid.0000000000000099

N/A

0DataRank · unranked

1 citations

Erin F. Barreto, Kristin C. Mara, Andrew D. Rule, John C. Lieske, Callen D. Giesen +5 more

Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.01.010

N/A

0DataRank · unranked

2 citations

Bijan J. Borah, James P. Moriarty, Ruchita Dholakia, Liuyan Jiang, Ke Li +6 more

Burkitt Lymphoma Presenting as Ileocolic Intussusception in an Adult

Open Journal of Blood Diseases(2023)10.4236/ojbd.2023.134014

N/A

0DataRank · unranked

1 citations

Bethany L Boyle, Kelsey Lynch, Anuradha Kanaparthi, Clifford Michael Csizmar, Daniel Philip Larson +5 more

Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7530

N/A

0DataRank · unranked

2 citations

Joselle Cook, Kah-Whye Peng, Susan Geyer, Brenda Ginos, Lianwen Zhang +7 more

Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14594

N/A

0DataRank · unranked

2 citations

Adam Remick, Nabila Nora Bennani, Joselle Cook, Lianwen Zhang, Thomas E. Witzig +9 more

Data from Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma

(2023)10.1158/1055-9965.c.6516286.v1

N/A

0DataRank · unranked

0 citations

Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan +8 more

Defining primary refractory large B-cell lymphoma

Blood Advances(2024)10.1182/bloodadvances.2024012760

N/A

0DataRank · unranked

32 citations

Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers +15 more

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL

Blood Cancer Journal(2024)10.1038/s41408-024-01080-0

N/A

0DataRank · unranked

12 citations

Matthew E. Stokes, Joseph P. Novak, Allison M. Bock, Sana Khan, Melissa A. Hopper +25 more

Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot

American Journal of Hematology(2024)10.1002/ajh.27533

N/A

0DataRank · unranked

9 citations

William R. Taylor, Douglas W. Mahoney, William R. Bamlet, Patrick H. Foote, Kelli N. Burger +15 more

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance

Hematological Oncology(2024)10.1002/hon.70006

N/A

0DataRank · unranked

2 citations

Kerstin Wenzl, Joseph P. Novak, Matthew E. Stokes, Melissa A. Hopper, Jordan E. Krull +17 more

Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101443

N/A

0DataRank · unranked

11 citations

Kerstin Wenzl, Melissa A. Hopper, Michelle K. Manske, Vivekananda Sarangi, Matthew J. Maurer +16 more

DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas

Blood Cancer Journal(2024)10.1038/s41408-024-01145-0

N/A

0DataRank · unranked

4 citations

Abigail R. Dropik, Janek S. Walker, Joseph P. Novak, M. Laverty, Michelle K. Manske +16 more

Hypomagnesemia in Large B cell Lymphoma patients receiving CAR T cell therapy correlates with immune dysregulation and decreased PFS: results from the ZUMA-1 trial and Mayo Clinic cohort

Research Square(2024)10.21203/rs.3.rs-4889200/v1

N/A

0DataRank · unranked

0 citations

Patrizia Mondello, Zixing Wang, Ying Li, Radhika Bansal, Sangeetha Gandhi +33 more

Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma

Blood Cancer Journal(2025)10.1038/s41408-025-01326-5

N/A

0DataRank · unranked

7 citations

Kerstin Wenzl, Joseph P. Novak, Matthew E. Stokes, Melissa A. Hopper, Abigail R. Dropik +17 more

Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma

Journal of Clinical Investigation(2025)10.1172/jci193006

N/A

0DataRank · unranked

6 citations

Shuhei Asada, Guangli Zhu, Yuna Hirohashi, Lisa A. Moreau, Divya Iyer +15 more

Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival

Experimental Hematology and Oncology(2025)10.1186/s40164-025-00623-w

N/A

0DataRank · unranked

1 citations

Patrizia Mondello, Zixing Wang, Ying Li, Radhika Bansal, Sangeetha Gandhi +33 more

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Blood Neoplasia(2025)10.1016/j.bneo.2025.100113

N/A

0DataRank · unranked

1 citations

Stephen M. Broski, Zequn Sun, Masha Kocherginsky, Betsy LaPlant, Matthew J. Maurer +10 more

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30067-3

N/A

0DataRank · unranked

29 citations

John P. Leonard, Thomas E. Witzig, Thomas M. Habermann, Kristie A. Blum, Nancy L. Bartlett +8 more

Testicular FDG‐PET/CT uptake threshold in aggressive lymphomas

American Journal of Hematology(2020)10.1002/ajh.26073

N/A

0DataRank · unranked

4 citations

Hidong Kim, Laura Harper, Thomas M. Habermann, Grzegorz S. Nowakowski, Carrie A. Thompson +8 more

Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8052

N/A

0DataRank · unranked

1 citations

Angelo Famà, Melissa C. Larson, Andew L. Feldman, Zhi-Zhang Yang, José C. Villasboas +13 more

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

UNC Libraries(2020)10.17615/y5gv-3561

N/A

0DataRank · unranked

0 citations

Anneclaire J. De Roos, Brian K. Link, Anne J. Novak, Yuanqing Ye, Mitchell J. Machiela +95 more

Thomas E. Witzig

Indexed papers

Top data-sharing exemplar

Papers